Halozyme Q3'26 Results Expected November 5
Halozyme Therapeutics is scheduled to report Q3'26 results after the market closes on November 5. Revenue and EPS estimates were provided.
Related stories
SelectQuote Reports Fiscal Q1 2027 Revenue of $280 Million
Revenue declined from $328.8 million a year earlier. Net loss narrowed to $20.3 million from $30.5 million, while adjusted EBITDA loss improved to $17.0 million from $32.1 million.
M impact | EQUITY | Nov 05, 2026, 02:05 PM UTC
electroCore Reports Record Q3 Sales, Lowers 2026 Revenue Guidance
Third-quarter net sales were a record $9.7 million. GAAP net loss improved by $2.0 million to $1.3 million, and Adjusted EBITDA loss narrowed to $0.7 million. electroCore lowered i
M impact | EQUITY | Nov 05, 2026, 02:05 PM UTC
Advanced Flower Capital Reports Third-Quarter 2026 Results
Advanced Flower Capital reported $8.6 million in investment income and $3.5 million in GAAP net investment income, or $0.16 per weighted average share. NAV per share rose to $8.55
M impact | EQUITY | Nov 05, 2026, 02:05 PM UTC
Outset Medical Reports Third-Quarter 2026 Revenue of $33.6 Million
Revenue increased 14% year over year. Net loss narrowed to $14.7 million, diluted loss per share improved to $0.78, and gross margin rose 130 basis points to 40.7%. The company rei
M impact | EQUITY | Nov 05, 2026, 02:05 PM UTC
Arq Reports Q3 2026 Results, Narrows Full-Year EBITDA Guidance
Arq reported revenue of $38.2 million, up 9% year over year, and net income of $2.5 million versus a $0.9 million loss. Adjusted EBITDA was $8.8 million. The company narrowed its 2
M impact | EQUITY | Nov 05, 2026, 02:05 PM UTC
Inseego Reports Q3 Revenue of $33.3 Million, Sets Q4 Guidance
Inseego reported Q3 2026 adjusted EBITDA of negative $1.0 million and a GAAP net loss of $8.1 million. It expects Q4 revenue of $56 million to $65 million and adjusted EBITDA of $0
M impact | EQUITY | Nov 05, 2026, 02:05 PM UTC